Skip Navigation


Annals of Oncology Advance Access originally published online on January 17, 2007
Annals of Oncology 2007 18(7):1159-1164; doi:10.1093/annonc/mdl477
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
18/7/1159    most recent
mdl477v1
Right arrow E-letters: Submit a response
Right arrow E-letters: View responses
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (1)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Lorusso, D
Right arrow Articles by Scambia, G
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lorusso, D
Right arrow Articles by Scambia, G
Related Collections
Right arrow 2007 - Review Articles
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2007 European Society for Medical Oncology

reviews

Pegylated liposomal doxorubicin-related palmar-plantar erythrodysesthesia (‘hand-foot’ syndrome)

D Lorusso1, A Di Stefano1, V Carone1, A Fagotti1, S Pisconti2 and G Scambia1,*

1 Department of Oncology, Catholic University of the Sacred Heart, Campobasso
2 Oncology Unit, SS Annunziata Hospital, Taranto, Italy

* Correspondence to: Dr G. Scambia, Gynecologic Oncology Unit, Catholic University of the Sacred Heart, Largo A.Gemelli 8, 00168 Rome, Italy. Tel/Fax: +39-06-35508736; E-mail: giovanni.scambia{at}rm.unicatt.it

Palmar-plantar erythrodysesthesia (PPE), also called hand-foot syndrome or hand-to-foot syndrome, is a distinctive and relatively frequent dermatologic toxic reaction associated with certain chemotherapeutic agents. Pegylated liposomal doxorubicin (PLD), a long-circulating formulation of doxorubicin in which doxorubicin hydrochloride is encapsulated within pegylated liposomes, is approved to treat patients with metastatic breast cancer, advanced ovarian cancer, and acquired immunodeficiency syndrome-related Kaposi's sarcoma. The incidence of PPE is increased in patients receiving PLD compared with conventional doxorubicin. In studies that utilized the currently approved dose of PLD (50 mg/m2 every 4 weeks), ~50% of all patients receiving PLD experienced PPE, and ~20% experienced grade 3 PPE. The pathophysiology of PPE, as it occurs with any drug with which it is associated, is not well understood. Studies evaluating the development of PPE specifically associated with PLD have not fully elucidated the mechanism; however, data support the roles of drug excretion in sweat and local pressure as contributors. When PPE develops, clinical interventions with respect to altering PLD administration include dose reduction, less frequent dosing, and ultimately, drug withdrawal with several consequences on treatment efficacy. This article will review the available data regarding the etiology and potential management strategies of PPE associated with PLD.

Key words: hand-foot syndrome, liposomal doxorubicin, pegylated

Received for publication September 8, 2006. Revision received October 30, 2006. Accepted for publication November 22, 2006.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Ann OncolHome page
M. E. Lacouture, L. M. Reilly, P. Gerami, and J. Guitart
Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib
Ann. Onc., November 1, 2008; 19(11): 1955 - 1961.
[Abstract] [Full Text] [PDF]

E-letters:

Read all E-letters

Dramatic improvement of palmar plantar erythrodysesthesia (PPE) with oral prednisone
Raja Jaber, et al.
Annals of Oncology, 11 Apr 2007 [Full text]

Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.